Antios' HBV collab axed after clinical hold, but biotech believes safety incident is not treatment-related
The FDA has placed a clinical hold on a Phase IIa study of Antios Therapeutics’ investigational hepatitis B med, CEO Greg Mayes confirmed to Endpoints News in an emailed statement.
A safety report was delivered to the biotech on May 17 after a patient dosed in a triple combination cohort of the study had experienced bradycardia and hypotension. The triple combo included Antios’ ATI-2173, Assembly Biosciences’ vebicorvir and Viread, an approved antiviral for HIV and hepatitis B.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.